Baseline characteristics
| . | N = 44 . |
|---|---|
| Age, y, median (range) | 63 (45-86) |
| Male, n (%) | 19 (43) |
| ECOG PS, n (%) | |
| 0 | 4 (9) |
| 1 | 23 (52) |
| 2 | 17 (38) |
| Cytogenetic/FISH markers, n (%) | |
| Standard risk | 23 (52) |
| High risk | 20 (45) |
| Unknown | 1 (2) |
| Creatinine clearance, n (%) | |
| <30 mL/min | 7 (16) |
| 30-60 mL/min | 13 (30) |
| >60 mL/min | 24 (55) |
| Prior lines of therapy, median (range) | 5 (1-11) |
| Prior therapy, n (%) | |
| Lenalidomide or thalidomide | 44 (100) |
| Bortezomib | 44 (100) |
| Autologous SCT | 32 (72) |
| Allogeneic SCT | 10 (22) |
| Alkylating agent | 42 (95) |
| Dexamethasone | 44 (100) |
| Anthracycline | 26 (59) |
| VDT-PACE or DCEP | 18 (41) |
| Refractory to prior therapy, n (%) | |
| Lenalidomide | 34 (77) |
| Bortezomib | 34 (77) |
| Bortezomib and lenalidomide | 28 (64) |
| . | N = 44 . |
|---|---|
| Age, y, median (range) | 63 (45-86) |
| Male, n (%) | 19 (43) |
| ECOG PS, n (%) | |
| 0 | 4 (9) |
| 1 | 23 (52) |
| 2 | 17 (38) |
| Cytogenetic/FISH markers, n (%) | |
| Standard risk | 23 (52) |
| High risk | 20 (45) |
| Unknown | 1 (2) |
| Creatinine clearance, n (%) | |
| <30 mL/min | 7 (16) |
| 30-60 mL/min | 13 (30) |
| >60 mL/min | 24 (55) |
| Prior lines of therapy, median (range) | 5 (1-11) |
| Prior therapy, n (%) | |
| Lenalidomide or thalidomide | 44 (100) |
| Bortezomib | 44 (100) |
| Autologous SCT | 32 (72) |
| Allogeneic SCT | 10 (22) |
| Alkylating agent | 42 (95) |
| Dexamethasone | 44 (100) |
| Anthracycline | 26 (59) |
| VDT-PACE or DCEP | 18 (41) |
| Refractory to prior therapy, n (%) | |
| Lenalidomide | 34 (77) |
| Bortezomib | 34 (77) |
| Bortezomib and lenalidomide | 28 (64) |
DCEP, dexamethasone, cyclophosphamide, etoposide, cisplatin; PS, performance status; VDT-PACE, bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide.